Zepp Health (NYSE:ZEPP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Zepp Health (NYSE:ZEPP) from a sell rating to a hold rating in a report published on Monday morning,Wall Street Zen reports.

Separately, Fundamental Research set a $53.01 target price on shares of Zepp Health and gave the company a “buy” rating in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $53.01.

Zepp Health Stock Down 1.2%

Shares of ZEPP stock opened at $4.98 on Monday. Zepp Health has a 12 month low of $3.85 and a 12 month high of $61.85. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 0.21. The firm has a market cap of $73.11 million, a PE ratio of -1.98 and a beta of 1.86. The stock has a 50 day moving average of $5.06 and a 200-day moving average of $10.70.

Insider Activity at Zepp Health

In other news, CFO Cheng Deng sold 9,836 shares of Zepp Health stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $4.61, for a total transaction of $45,343.96. Following the sale, the chief financial officer owned 114,539 shares of the company’s stock, valued at approximately $528,024.79. This trade represents a 7.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 36.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ZEPP. FIL Ltd bought a new stake in Zepp Health in the 4th quarter valued at $16,858,000. Millennium Management LLC lifted its holdings in shares of Zepp Health by 49.1% during the 4th quarter. Millennium Management LLC now owns 366,826 shares of the company’s stock worth $9,882,000 after acquiring an additional 120,750 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Zepp Health by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 295,967 shares of the company’s stock worth $7,974,000 after acquiring an additional 44,619 shares during the period. Balyasny Asset Management L.P. boosted its position in shares of Zepp Health by 46.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 202,775 shares of the company’s stock valued at $5,463,000 after acquiring an additional 64,692 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of Zepp Health by 16,412.0% during the 3rd quarter. UBS Group AG now owns 181,302 shares of the company’s stock valued at $8,300,000 after acquiring an additional 180,204 shares in the last quarter. 52.61% of the stock is currently owned by institutional investors and hedge funds.

About Zepp Health

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.